Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.55 USD | +5.57% | +6.58% | -18.59% |
Sales 2024 * | 189M 15.74B | Sales 2025 * | 165M 13.79B | Capitalization | 1.41B 118B |
---|---|---|---|---|---|
Net income 2024 * | -325M -27.1B | Net income 2025 * | -382M -31.85B | EV / Sales 2024 * | 4.26 x |
Net cash position 2024 * | 610M 50.86B | Net cash position 2025 * | 270M 22.47B | EV / Sales 2025 * | 6.92 x |
P/E ratio 2024 * |
-4.04
x | P/E ratio 2025 * |
-3.64
x | Employees | 577 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 58.87% |
Latest transcript on Arcus Biosciences, Inc.
1 day | +5.57% | ||
1 week | +6.58% | ||
Current month | -17.64% | ||
1 month | -6.61% | ||
3 months | +2.78% | ||
6 months | -2.32% | ||
Current year | -18.59% |
Managers | Title | Age | Since |
---|---|---|---|
Juan Jaen
FOU | Founder | 66 | 01/15/01 |
Terry Rosen
CEO | Chief Executive Officer | 64 | 01/15/01 |
Robert Goeltz
DFI | Director of Finance/CFO | 51 | 01/20/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Terry Rosen
CEO | Chief Executive Officer | 64 | 01/15/01 |
Kathryn Falberg
BRD | Director/Board Member | 63 | 18/17/18 |
Yasunori Kaneko
BRD | Director/Board Member | 69 | 01/15/01 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.88% | 11 M€ | -6.03% | - | |
0.28% | 27 M€ | -5.03% | - | |
0.12% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 15.55 | +5.57% | 505,353 |
25/24/25 | 14.73 | -4.54% | 475,001 |
24/24/24 | 15.43 | -0.45% | 524,078 |
23/24/23 | 15.5 | +5.59% | 582,461 |
22/24/22 | 14.68 | +0.62% | 450,974 |
Delayed Quote Nyse, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.59% | 1.41B | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- RCUS Stock